申请人:Piqur Therapeutics AG
公开号:US10640516B2
公开(公告)日:2020-05-05
The invention relates to novel phosphoinositide 3-kinase (PI3k), mammalian target of rapamycin (mTOR) and PI3k-related kinase (PIKKs) inhibitor compounds of formula (I),
wherein X1, X2 and X3 are N or CH, with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH, These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.
本发明涉及新型磷酸肌醇 3-激酶 (PI3k)、哺乳动物雷帕霉素靶标 (mTOR) 和 PI3k 相关激酶 (PIKKs) 的式 (I) 抑制剂化合物、
其中 X1、X2 和 X3 是 N 或 CH,但条件是 X1、X2 和 X3 中至少有两个是 N;Y 是 N 或 CH,这些化合物可单独使用或与其它治疗剂结合使用,用于治疗由脂质激酶介导的疾病。